RNA bacteriophage capsid-mediated drug delivery and epitope presentation

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 371-380

  Brown, William L ^a   Mastico, Robert A ^a   Wu, Min ^a   Heal, Karen G ^a   Adams, Chris J ^a   Murray, James B ^a   Simpson, Jeremy C ^b   Lord, J Michael ^b   Taylor Robinson, Andrew W ^a   Stockley, Peter G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Chimera; MS2 virus like particle; Ricin A chain; Synthetic vaccine

Indexed keywords

CHIMERIC PROTEIN; COAT PROTEIN; CYTOKINE; EPITOPE; NUCLEIC ACID; NUCLEOTIDE; RICIN A; VIRUS PROTEIN; VIRUS RNA;

B LYMPHOCYTE; BACTERIOPHAGE; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LD 50; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS CAPSID;

AMINO ACID SEQUENCE; ANIMALS; CAPSID PROTEINS; CYTOKINES; DRUG DELIVERY SYSTEMS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; IMMUNOCONJUGATES; LEVIVIRUS; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; RNA-BINDING PROTEINS; VACCINES, SYNTHETIC; VIRION;

MIRIDAE;

EID: 0036980063     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067930     Document Type: Conference Paper

References (48)

1. Zinder N (ed): RNA Phages. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1975.
2. Kraemer B, Zhang B, SenGupta D, Fields S, Wickens M: Using the yeast three-hybrid system to detect and analyze RNA-protein interactions. Methods Enzymol 2000;328:297-321.
3. Witherell GW, Gott JM, Uhlenbeck OC: Specific interaction between RNA phage coat proteins and RNA. Prog Nucleic Acid Res Mol Biol 1991;40:185-220.
4. Stockley PG, Stonehouse NJ, Valegård K: Molecular mechanisms of RNA phage morphogenesis. Int J Biochem 1994;26:1249-1260.
5. Steitz JA: Specific recognition of the isolated R17 replicase initiator region by R17 coat protein. Nature 1974;248:223-225.
6. Beckett D, Uhlenbeck OC: Ribonucleo-protein complexes of R17 coat protein and a translation operator analog. J Mol Biol 1988;204:927-938.
7. Beckett D, Wu HN, Uhlenbeck OC: Roles of operator and non-operator RNA sequences in bacteriophage R17 capsid assembly. J Mol Biol 1988;204:939-947.
8. Ling CM, Hung PP, Overby LR: Independent assembly of Qβ and MS2 phages in doubly infected Escherichia coli. Virology 1970;40: 920-929.
9. Spingola M, Peabody DS: MS2 coat protein mutants which bind Qbeta RNA. Nucleic Acids Res 1997;25:2808-2815.
10. Stockley PG, Stonehouse NJ, Murray JB, Goodman STS, Talbot SJ, Adams CJ, Liljas L, Valegård K: Probing sequence-specific RNA recognition by the bacteriophage MS2 coat protein. Nucleic Acids Res 1995;15:575-594.
11. Dertinger D, Uhlenbeck OC: Evaluation of methylphosphonates as analogs for detecting phosphate contacts in RNA-protein complexes. RNA 2001;7:622-631.
12. Stockley PG, Stonehouse NJ, Walton C, Walters DA, Medina C, Macedo MB, Hill HR, Goodman STS, Talbot SJ, Tewary HK, Golmohammadi R, Liljas L, Valegård K: Molecular mechanism of RNA-phage morphogenesis. Biochem Soc Trans 1993;21:627-633.
13. Peabody DS: The RNA biding site of bacteriophage MS2 coat protein. EMBO J 1993;12: 595-600.
14. Tars K, Fridborg K, Bundule M, Liljas L: The three-dimensional structure of bacteriophage PP7 from Pseudomonas aeruginosa at 3.7-A resolution. Virology 2000;272:331-337.
15. Tars K, Bundule M, Fridborg K, Liljas L: The crystal structure of bacteriophage GA and a comparison of bacteriophages belonging to the major groups of Escherichia coli leviviruses. J Mol Biol 1997;271:759-773.
16. Golmohammadi R, Valegård K, Fridborg K, Liljas L: The refined structure of bacteriophage MS2 at 2.8 A resolution. J Mol Biol 1993;234:620-639.
17. Mastico RA, Talbot SJ, Stockley PG: Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J Gen Virol 1993;74:541-548.
18. Valegård K, Murray JB, Stockley PG, Stonehouse NJ, Liljas L: Crystal structure of an RNA bacteriophage coat protein-operator complex. Nature 1994;371:623-626.
19. Valegård K, Murray JB, Stonehouse NJ, van den Worm S, Stockley PG, Liljas L: The three dimensional structures of two complexes between recombinant MS2 capsids and RNA operator fragments reveal sequence-specific protein-RNA interactions. J Mol Biol 1997;270:724-738.
20. Grahn E, Stonehouse NJ, Murray JB, van den Worm S, Valegård K, Fridborg K, Stockley PG, Liljas L: Crystallographic studies of RNA hairpins in complexes with recombinant MS2 capsids: Implications for binding requirements. RNA 1999;4:131-138.
21. Grahn E, Stonehouse NJ, Adams CJ, Fridborg K, Beigelman L, Matulic-Adamic J, Warriner SL, Stockley PG, Liljas L: Deletion of a single hydrogen bonding atom from the MS2 RNA operator leads to dramatic rearrangements at the RNA-coat protein interface. Nucleic Acids Res 2000;28:4611-4616.
22. Grahn E, Moss T, Helgstrand C, Fridborg K, Sundaram M, Tars K, Lago H, Stonehouse NJ, Davis DR, Stockley PG, Liljas L: Structural basis of pyrimidine specificity in the MS2 RNA hairpin-coat-protein complex. RNA 2001;7:1616-1627.
23. Convery MA, Rowsell S, Stonehouse NJ, Ellington AD, Hirao I, Murray JB, Peabody DS, Phillips SEV, Stockley PG: Crystal structure of an RNA aptamer-protein complex at 2.8 A resolution. Nat Struct Biol 1998;5:133-139.
24. Rowsell S, Stonehouse NJ, Convery MA, Adams CJ, Ellington AD, Hirao L, Peabody DS, Stockley PG, Phillips SEV: Crystal structures of a series of RNA aptamers complexed to the same protein target. Nat Struct Biol 1998;5:970-975.
25. van den Worm SHE, Stonehouse NJ, Valegård K, Murray JB, Walton C, Fridborg K, Stockley PG, Liljas L: Crystal structures of MS2 coat protein mutants in complex with wild-type RNA operator fragments. Nucleic Acids Res 1998;26:1345-1351.
26. Stockley PG, Mastico RA: Use of fusions to viral coat proteins as antigenic carriers for vaccine development. Methods Enzymol 2000;326:551-569.
27. Wu M, Brown WL, Stockley PG: Cell-specific delivery of bacteriophage-encapsidated ricin A chain. Bioconjug Chem 1995;6:587-595.
28. Pushko P, Kozlovskaya T, Sominskaya I, Brede A, Stankevica E, Ose V, Pumpens P, Grens E: Analysis of RNA phage fr coat protein assembly by insertion, deletion and substitution mutagenesis. Protein Eng 1993;6:883-891.
29. Murray JB, Collier AK, Arnold JRP: A general purification procedure for chemically synthesized oligonucleotides. Anal Biochem 1994;218:177-184.
30. Wales R, Roberts LM, Lord JM: Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells. J Biol Chem 1993;268:23986-23990.
31. Porta C, Spall VE, Loveland J, Johnson JE, Barker PJ, Lomonossoff GP: Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 1994;202:949-955.
32. Uhr JW, Finkelstein MS: The kinetics of antibody formation. Prog Allergy 1967;10:37-83.
33. Hollingdale MR, Taylor-Robinson AW, Krzych U: Immune responses to liver stage parasites: Implications for vaccine development; in Perlmann P, Troye-Blomberg M (eds): Malaria Immunology. Chem Immunol. Basel, Karger, 2002, vol 80, p 97-124.
34. Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW: Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine 1999;18:251-258.
35. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee H-G: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
36. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987;330:664-666.
37. Wu M, Miyazawa M, Nose M: Immunotoxins as a new reagent for treatment of viral infection and autoimmune diseases. Drug Deliv Syst 1993;8:5-10.
38. Wu M: Enhancement of immunotoxin activity using chemical and biological reagents. Br J Cancer 1997;75:1347-1355.
39. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-232.
40. Abe M, Kufe D: Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res 1984;44:4574-4577.
41. Tondini C, Hayes FD, Gelman R, Henderson IC, Kufe DW: Comparison of CA15-3 and CEA in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-4112.
42. Abe M, Kufe D: Structural analysis of the DF3 human breast carcinoma-associated protein. Cancer Res 1989;49:2834-2839.
43. Perey L, Hayes DF, Maimonis P, Abe M, O'Hara C, Kufe DW: Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 1992;52:2563-2568.
44. Brown WL: Applications of MS2 Capsid-Like Particles as an Oligonucleotide Cell Delivery System; PhD thesis, Leeds, 1999.
45. Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR: Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982;42:4413-4420.
46. Stubenrauch K, Gleiter S, Brinkmann U, Rudolph R, Lilie H: Conjugation of an antibody Fv fragment to a virus coat protein. Cell-specific targeting of recombinant polyoma-virus-like particles. Biochem J 2001;356:867-873.
47. Uppala A, Koivunen E: Targeting of phage display vectors to mammalian cells. Comb Chem High Throughput Screen 2000;3:373-392.
48. van Meerten D, Olsthoorn RC, van Duin J, Verhaert RM: Peptide display on live MS2 phage: Restrictions at the RNA genome level. J Gen Virol 2001;82:1797-1805.